|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
564,050,000 |
Market
Cap: |
54.09(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.0959 - $0.0959 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Zomedica is a biopharmaceutical company targeting health and wellness solutions for the companion pet. Co.'s primary drug product candidate is ZM-007, an oral suspension formulation of metronidazole, targeting the treatment of acute diarrhea in small dog breeds and puppies under nine pounds or four kilograms. Co.'s second drug product candidate is ZM-012, a tablet formulation of metronidazole and a complementary formulation to ZM-007, targeting the treatment of acute diarrhea in dogs. Co.'s third drug product candidate is ZM-006, a transdermal gel formulation of methimazole targeting the chronic treatment of hyperthyroidism in cats.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
300,000 |
1,850,000 |
2,400,000 |
2,600,000 |
Total Buy Value |
$39,600 |
$273,199 |
$365,349 |
$403,779 |
Total People Bought |
3 |
5 |
5 |
5 |
Total Buy Transactions |
3 |
13 |
18 |
20 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Cotter Ann |
CFO and Secretary |
|
2021-04-12 |
4 |
OE |
$0.11 |
$9,083 |
D/D |
58,332 |
25,000 |
|
- |
|
Powers Johnny |
Director |
|
2021-04-12 |
4 |
OE |
$0.16 |
$100,000 |
D/D |
625,000 |
1,250,000 |
|
- |
|
Powers Johnny |
Director |
|
2021-04-12 |
4 |
AS |
$1.16 |
$867,525 |
D/D |
(750,000) |
625,000 |
|
- |
|
Powers Johnny |
Director |
|
2021-04-12 |
4 |
OE |
$0.26 |
$340,000 |
D/D |
750,000 |
875,000 |
|
- |
|
Macleod Christopher Ross |
Director |
|
2021-02-03 |
4 |
S |
$1.10 |
$7,047 |
D/D |
(6,400) |
0 |
|
- |
|
Macleod Christopher Ross |
Director |
|
2020-07-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,400 |
|
- |
|
Powers Johnny |
Director |
|
2020-07-07 |
4 |
B |
$0.16 |
$100,000 |
D/D |
625,000 |
625,000 |
2.39 |
- |
|
Solensky Gerald Jr |
President and CEO |
|
2019-03-29 |
4 |
OE |
$1.52 |
$99,999 |
D/D |
65,789 |
38,545,671 |
|
- |
|
Solensky Gerald Jr |
President and CEO |
|
2019-03-15 |
4 |
OE |
$1.52 |
$249,999 |
D/D |
164,473 |
38,479,882 |
|
- |
|
Solensky Gerald Jr |
President and CEO |
|
2019-03-08 |
4 |
OE |
$1.52 |
$249,999 |
D/D |
164,473 |
38,315,409 |
|
- |
|
Williams Rodney James |
Director |
|
2018-12-20 |
4 |
OE |
$1.20 |
$32,280 |
D/D |
26,900 |
161,900 |
|
- |
|
Rowe Jeffrey M |
Director |
|
2018-11-29 |
4 |
OE |
$1.20 |
$210,000 |
D/D |
175,000 |
275,000 |
|
- |
|
Solensky Gerald Jr |
President and CEO |
|
2018-10-11 |
4 |
OE |
$1.20 |
$240,000 |
D/D |
200,000 |
38,151,100 |
|
- |
|
Solensky Gerald Jr |
President and CEO |
|
2018-10-02 |
4/A |
S |
$1.89 |
$310 |
D/D |
(164) |
37,950,936 |
|
- |
|
Lebar James |
Director |
|
2018-08-28 |
4 |
S |
$2.15 |
$430,000 |
D/D |
(200,000) |
20,000 |
|
- |
|
Williams Rodney James |
Director |
|
2018-06-11 |
4 |
S |
$1.92 |
$1,920 |
D/D |
(1,000) |
135,000 |
|
- |
|
Williams Rodney James |
Director |
|
2018-06-01 |
4 |
S |
$1.93 |
$965 |
D/D |
(500) |
136,000 |
|
- |
|
Williams Rodney James |
Director |
|
2018-05-31 |
4 |
S |
$1.91 |
$2,865 |
D/D |
(1,500) |
136,500 |
|
- |
|
Williams Rodney James |
Director |
|
2018-05-24 |
4 |
S |
$1.92 |
$960 |
D/D |
(500) |
138,000 |
|
- |
|
Williams Rodney James |
Director |
|
2018-05-23 |
4 |
S |
$1.91 |
$959 |
D/D |
(500) |
138,500 |
|
- |
|
Williams Rodney James |
Director |
|
2018-05-22 |
4 |
S |
$1.93 |
$965 |
D/D |
(500) |
139,000 |
|
- |
|
Williams Rodney James |
Director |
|
2018-05-21 |
4 |
S |
$2.00 |
$1,003 |
D/D |
(500) |
139,500 |
|
- |
|
Morley Stephanie |
COO & VP of Product Dev |
|
2018-04-20 |
4 |
OE |
$0.20 |
$20,800 |
D/D |
104,000 |
1,459,580 |
|
- |
|
Morley Stephanie |
COO & VP of Product Dev |
|
2018-03-29 |
4 |
OE |
$0.20 |
$100,000 |
D/D |
500,000 |
1,355,580 |
|
- |
|
Herbst Bruk |
Chief Commercial Officer |
|
2018-03-29 |
4 |
OE |
$2.20 |
$138,591 |
D/D |
62,996 |
62,996 |
|
- |
|
56 Records found
|
|
Page 2 of 3 |
|
|